Cart
sales@molnova.com
Alflutinib
CAS No. 1869057-83-9
Alflutinib( AST2818 | AST-2818 | ASK120067 )
Catalog No. M12888 CAS No. 1869057-83-9
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 155 | In Stock |
|
| 5MG | 123 | In Stock |
|
| 10MG | 187 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 554 | In Stock |
|
| 100MG | 731 | In Stock |
|
| 200MG | 1042 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlflutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
-
DescriptionAlflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical.
-
In VitroFirmonertinib is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
-
In Vivo——
-
SynonymsAST2818 | AST-2818 | ASK120067
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1869057-83-9
-
Formula Weight568.605
-
Molecular FormulaC28H31F3N8O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C
-
Chemical NameN-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914.
molnova catalog
related products
-
Desmethyl Erlotinib
OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
-
CHMFL-EGFR-202
CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
